Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Efficacy of Combined Antithrombotic Treatment with Strong Antiplatelet Agents in Patients with Atrial Fibrillation and Acute Coronary Syndrome: A Randomized Controlled Study

  • By

  • Konstantinos D. Rizas

  • Konstantinos Mourouzis

  • Dominik Rath

  • Christoph B. Olivier

  • Laura Elisa Villegas Sierra

  • Theofanis Korovesis

  • Amin Polzin

  • Amani Al Tawil

  • Reza Wakili

  • Lukas von Stuelpnagel

  • Katharina Mayer

  • Marion Janisch

  • Tanja Ulrich

  • Sarah Lang

  • Sebastian K. G. Maier

  • Florian Brattinger

  • Lorenz Bott-Flügel

  • Harilaos Bogossian

  • Konstantinos Iliodromitis

  • Luisa Freyer

  • Julius Steffen

  • Konstantin Stark

  • Elodie Eiffener

  • Lauren E. Sams

  • Tobias Petzold

  • Axel Linke

  • Felix M. Heidrich

  • Samuel Sossala

  • Saif Zako

  • Nikolaos Dagkonakis

  • Andreas Schäfer

  • Frank Edelmann

  • David M. Leistner

  • Mariya Maslarska

  • Fabian Knebel

  • Georg Nickenig

  • Blerim Luani

  • Tienush Rassaf

  • Hüseyin Ince

  • Ibrahim Akin

  • Micha T. Maeder

  • Meinrad Gawaz

  • Hans-Josef Feistritzer

  • Norbert Frey

  • Stefan Kääb

  • Riza Sahin

  • Matthias Pauschinger

  • Thomas Stiermaier

  • Ingo Eitel

  • Marc Kollum

  • Jan Sebastian Wolter

  • Michael Schreinlechner

  • Axel Bauer

  • Christoph Stellbrink

  • Ulf Landmesser

  • Paulus Kirchhof

  • Dirk Sibbing

  • Holger Thiele

  • Adnan Kastrati

  • Ulrich Mansmann

  • Steffen Massberg

  • August 29, 2026

Share

  • 1

    The EPIDAURUS trial evaluated dual antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome after PCI.

  • 2

    The trial was stopped prematurely due to low probability of experimental intervention superiority and safety concerns.

  • 3

    A total of 602 patients were enrolled, with a median age of 78 years and a CHA2DS2-VASc score indicating high stroke risk.

  • 4

    Potent P2Y12 inhibitors were administered to 96.2% of the experimental group, while 99.3% of the control group received clopidogrel.

  • 5

    The primary efficacy analysis at 6 weeks post-randomization produced a win-loss ratio of 1.19, indicating no significant benefit.

Original Source(s)

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial

  • by Konstantinos D. Rizas, Konstantinos Mourouzis, Dominik Rath, Christoph B. Olivier, Laura Elisa Villegas Sierra, Theofanis Korovesis, Amin Polzin, Amani Al Tawil, Reza Wakili, Lukas von Stuelpnagel, Katharina Mayer, Marion Janisch, Tanja Ulrich, Sarah Lang, Sebastian K. G. Maier, Florian Brattinger, Lorenz Bott-Flügel, Harilaos Bogossian, Konstantinos Iliodromitis, Luisa Freyer, Julius Steffen, Konstantin Stark, Elodie Eiffener, Lauren E. Sams, Tobias Petzold, Axel Linke, Felix M. Heidrich, Samuel Sossala, Saif Zako, Nikolaos Dagkonakis, Andreas Schäfer, Frank Edelmann, David M. Leistner, Mariya Maslarska, Fabian Knebel, Georg Nickenig, Blerim Luani, Tienush Rassaf, Hüseyin Ince, Ibrahim Akin, Micha T. Maeder, Meinrad Gawaz, Hans-Josef Feistritzer, Norbert Frey, Stefan Kääb, Riza Sahin, Matthias Pauschinger, Thomas Stiermaier, Ingo Eitel, Marc Kollum, Jan Sebastian Wolter, Michael Schreinlechner, Axel Bauer, Christoph Stellbrink, Ulf Landmesser, Paulus Kirchhof, Dirk Sibbing, Holger Thiele, Adnan Kastrati, Ulrich Mansmann, Steffen Massberg

  • August 29, 2026

Related Content

ASE Plenary: Progress, Priorities, and What’s Next

Efforts to align, sustain, and engage drove a year of growth for ASE.

FDA Classifies Medtronic Harmony Recall as Class I

Distal tip detachment during implantation may necessitate retrieval of the detached tip through an endovascular or surgical procedure.

Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis